Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16766999 | 0.88 | LMNA (0.36) | METAP2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL8431086 | 0.80 | METAP2 (0.35) | METAP2RAB9ASMN1; SMN2NPC1ERBB2 | |
| SCHEMBL6344688 | 0.77 | MAPT (0.46) | RAB9ASMN1; SMN2NPC1MAPTALDH1A1 | |
| SCHEMBL989177 | 0.77 | CA12 (0.42) | RAB9ASMN1; SMN2NPC1ATMMAPT | |
| SCHEMBL1645103 | 0.77 | METAP2 (0.50) | METAP2RAB9ANPC1MAPTMEN1 | |
| SCHEMBL2765284 | 0.77 | KMT2A (0.52) | METAP2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL1926319 | 0.77 | METAP2 (0.50) | METAP2RAB9ASMN1; SMN2NPC1MAPT | |
| SCHEMBL8486152 | 0.77 | LMNA (0.35) | MEN1KMT2ACYP1A2LMNA | |
| SCHEMBL1260621 | 0.77 | LMNA (0.32) | MEN1KMT2ALMNA | |
| SCHEMBL3442252 | 0.77 | METAP2 (0.50) | METAP2RAB9ASMN1; SMN2NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674200-B | A kind of compound and its preparation method and application containing L- prolineamide segment | 西安交通大学 | 2019-04-12 | — | — | CN | claimed |
| CN-1668595-A | Method for forming carbon-carbon or carbon-heteroatom bonds | RHONE POULENC CHIMIE (FR) | 2005-09-14 | — | — | CN | claimed |
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-110483400-B | Preparation method of pyrazole derivative | 上海应用技术大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-110372636-B | Glucose ceramide synthase inhibitors for the treatment of diseases | 生物马林药物股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912977-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3046920-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARM INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARM INC (US) | 2021-02-23 | — | — | US | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060111380-A1 | Novel azole derivatives | MSD K.K. (JP) | 2006-05-25 | — | — | US | disclosed |
| CN-1668595-A | Method for forming carbon-carbon or carbon-heteroatom bonds | RHONE POULENC CHIMIE (FR) | 2005-09-14 | — | — | CN | disclosed |
| EP-1566384-A1 | NOVEL AZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-24 | — | — | EP | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| CN-1049658-C | Pyrazolo[4,3-c]pyridines, a process for their preparation and their use as serotonin reuptake inhibitors | HOECHST MARION ROUSSEL INC (US) | 2000-02-23 | — | — | CN | disclosed |
| CN-1099033-A | Pyrazolo [4,3-c] pyridine, their preparation method and as the purposes of serotonin reuptake inhibitors | HOECHST ROUSSEL PHARMA (US) | 1995-02-22 | — | — | CN | disclosed |
| US-4950678-A | PESTICIDES | SANDOZ LTD. (CH) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927092-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | METAP2 1552/4885RAB9A 1370/4885SMN1; SMN2 1269/4885 |
| US-20060111380-A1 | Novel azole derivatives | NPY1R, NPY5R, NPY2R | METAP2 1296/4885RAB9A 2739/4885SMN1; SMN2 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.